Subcommittee on Psychopharmacology
This committee reviews Evidence based and Patient -centered Psychopharmacology
MD and DO
1. Review important evidence -based findings in psychopharmacology and relevant drug warnings (eg, from the FDA).
2. Assess current (individual and group) psychiatric practice patterns in the context of the standard of care and new evidence.
3. Integrate evidence on psychosocial/psychodynamic aspects of prescribing process.
4. Investigate institutional systems for delivery of pharmacologic care (including informatics) for system improvement.
John Azer, MD
Marina Bayeva, MD
Charlie Blomquist, MD
Vivian Chan, DO
Heather Forouhar, MD
Samar Habl, MD
Nick Holiday, MD
David Mintz, MD
Eric Plakun, MD
Kyle Shepard, DO
Margaret Parish, PhD
Austen Riggs Center Inc. confirms that Subcommittee members listed above, nor anyone involved in the planning of the CME event, has disclosed a potential conflict of interest.
The Austen Riggs Center designates this live activity for a maximum of 17 AMA PRA Category1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The Austen Riggs Center is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
This live activity is approved for up to 17 hours of AMA PRA Category 1 Credit(s)™, risk management study.
- 17.00 AMA PRA Category 1 Credit™Austen Riggs Center,Inc. is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians. Austen Riggs Center, Inc. designates this Live for a maximum of 17.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 17.00 Risk Management Study17.00 meet the criteria of the Massachusetts Board of Registration in Medicine's for risk management study.